Bone Biologics (BBLG) - רווח נקי למניה (EPS TTM)

Bone Biologics minimizes costs by outsourcing development and testing. Net income per unit over the last 12 months demonstrates the impact of this strategy, where the -1.62 indicator determines the metric's magnitude. However, the long road to commercialization and dependence on capital create risks, which Bone Biologics balances by implementing environmental ESG standards and strict bioethical production controls.

For Bone Biologics (BBLG), which develops innovative scaffolds for bone regeneration, the change in earnings per share over the last 12 months reflects the monetization efficiency of its medical technologies. This indicator is calculated by dividing the total annual net income by the number of outstanding shares. The metric measures the actual capital growth available to each shareholder. Positive momentum confirms the financial stability of the business. It is critical for investors to avoid purchasing the asset at the peak of a speculative impulse.